Paula Marrano

5.2k total citations · 2 hit papers
60 papers, 4.0k citations indexed

About

Paula Marrano is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Paula Marrano has authored 60 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Molecular Biology, 19 papers in Pulmonary and Respiratory Medicine and 16 papers in Genetics. Recurrent topics in Paula Marrano's work include Neuroblastoma Research and Treatments (14 papers), Genomic variations and chromosomal abnormalities (12 papers) and Sarcoma Diagnosis and Treatment (11 papers). Paula Marrano is often cited by papers focused on Neuroblastoma Research and Treatments (14 papers), Genomic variations and chromosomal abnormalities (12 papers) and Sarcoma Diagnosis and Treatment (11 papers). Paula Marrano collaborates with scholars based in Canada, United States and Thailand. Paula Marrano's co-authors include Jeremy A. Squire, Paul S. Thorner, Suzanne Kamel‐Reid, Gilda da Cunha Santos, Ming‐Sound Tsao, Tong Zhang, Chang‐Qi Zhu, Lesley Seymour, Jean-Claude Cutz and Keyue Ding and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

Paula Marrano

60 papers receiving 3.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome

2005 1.5k citations Ming‐Sound Tsao, Akira Sakurada et al. New England Journal of Medicine profile →
Role of KRAS and EGFR As Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21

2008 561 citations Chang‐Qi Zhu, Gilda da Cunha Santos et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Paula Marrano Canada	26	2.2k	2.0k	1.6k	842	366	60	4.0k
David Hogg Canada	40	1.1k 0.5×	4.0k 2.0×	3.3k 2.0×	726 0.9×	418 1.1×	124	6.3k
Irina A. Lubensky United States	34	1.1k 0.5×	1.3k 0.7×	1.6k 1.0×	1.2k 1.4×	372 1.0×	65	3.8k
Federico A. Monzon United States	34	1.4k 0.6×	1.6k 0.8×	2.2k 1.4×	1.5k 1.8×	388 1.1×	114	4.4k
Lara Felicioni Italy	26	2.2k 1.0×	1.9k 1.0×	1.6k 1.0×	1.4k 1.6×	91 0.2×	37	3.7k
Gaia Schiavon United Kingdom	28	1.7k 0.8×	2.5k 1.3×	1.5k 0.9×	1.9k 2.2×	339 0.9×	105	4.6k
Tim Forshew United Kingdom	23	2.1k 0.9×	2.2k 1.1×	2.6k 1.5×	4.1k 4.9×	309 0.8×	34	5.9k
Maija Tarkkanen Finland	28	1.5k 0.7×	889 0.5×	1.3k 0.8×	771 0.9×	711 1.9×	75	3.1k
Alexander Guminski Australia	30	1.2k 0.6×	3.1k 1.6×	1.1k 0.7×	350 0.4×	102 0.3×	114	4.2k
Mark Sausen United States	20	921 0.4×	1.2k 0.6×	1.2k 0.8×	1.8k 2.2×	245 0.7×	51	3.1k
Roland Penzel Germany	40	1.5k 0.7×	1.8k 0.9×	1.7k 1.0×	1.3k 1.5×	202 0.6×	134	4.4k

Countries citing papers authored by Paula Marrano

Since Specialization

Citations

This map shows the geographic impact of Paula Marrano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paula Marrano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paula Marrano more than expected).

Fields of papers citing papers by Paula Marrano

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paula Marrano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paula Marrano. The network helps show where Paula Marrano may publish in the future.

Co-authorship network of co-authors of Paula Marrano

This figure shows the co-authorship network connecting the top 25 collaborators of Paula Marrano. A scholar is included among the top collaborators of Paula Marrano based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paula Marrano. Paula Marrano is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Thorner, Paul S., Anne‐Sophie Chong, Javad Nadaf, et al.. (2022). PRAME protein expression in DICER1‐related tumours. The Journal of Pathology Clinical Research. 8(3). 294–304. 6 indexed citations

Chung, Catherine T., Cristina R. Antonescu, Brendan C. Dickson, et al.. (2020). Pediatric fibromyxoid soft tissue tumor with PLAG1 fusion: A novel entity?. Genes Chromosomes and Cancer. 60(4). 263–271. 20 indexed citations

Zhang, Libo, Paula Marrano, Bing Wu, et al.. (2015). Combined Antitumor Therapy with Metronomic Topotecan and Hypoxia-Activated Prodrug, Evofosfamide, in Neuroblastoma and Rhabdomyosarcoma Preclinical Models. Clinical Cancer Research. 22(11). 2697–2708. 25 indexed citations

Marrano, Paula, et al.. (2015). MIB-1 Index as a Surrogate for Mitosis-Karyorrhexis Index in Neuroblastoma. The American Journal of Surgical Pathology. 39(8). 1054–1060. 10 indexed citations

Zhang, Libo, Paula Marrano, Sushil Kumar, et al.. (2013). Nab-Paclitaxel Is an Active Drug in Preclinical Model of Pediatric Solid Tumors. Clinical Cancer Research. 19(21). 5972–5983. 48 indexed citations

Pandita, Ajay, Jane Bayani, Jana Paděrová, et al.. (2011). Integrated Cytogenetic and High-Resolution Array CGH Analysis of Genomic Alterations Associated with <i>MYCN</i> Amplification. Cytogenetic and Genome Research. 134(1). 27–39. 5 indexed citations

Shuangshoti, Shanop, et al.. (2011). Natural course of low risk neuroblastoma. Pediatric Blood & Cancer. 58(5). 690–694. 11 indexed citations

Tanboon, Jantima, et al.. (2011). Primary intracranial Ewing sarcoma with an unusually aggressive course: A case report and review of the literature. Neuropathology. 32(3). 293–300. 27 indexed citations

Joshua, Anthony M., Erica Shen, Maisa Yoshimoto, et al.. (2010). Topographical analysis of telomere length and correlation with genomic instability in whole mount prostatectomies. The Prostate. 71(7). 778–790. 19 indexed citations

10.

Zhu, Chang‐Qi, Gilda da Cunha Santos, Keyue Ding, et al.. (2008). Role of KRAS and EGFR As Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. Journal of Clinical Oncology. 26(26). 4268–4275. 561 indexed citations breakdown →

11.

Bernardini, Marcus Q., Anya Tsalenko, Paula Marrano, et al.. (2008). High definition cytogenetics and oligonucleotide aCGH analyses of cisplatin‐resistant ovarian cancer cells. Genes Chromosomes and Cancer. 47(5). 427–436. 16 indexed citations

12.

Vukovic, Bisera, et al.. (2006). Large scale copy number variation (CNV) at 14q12 is associated with the presence of genomic abnormalities in neoplasia. BMC Genomics. 7(1). 138–138. 23 indexed citations

13.

Tsao, Ming‐Sound, Akira Sakurada, Jean-Claude Cutz, et al.. (2005). Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome. New England Journal of Medicine. 353(2). 133–144. 1483 indexed citations breakdown →

14.

Evans, Andrew, Brenda L. Gallie, Michael A.S. Jewett, et al.. (2004). Defining a 0.5-Mb Region of Genomic Gain on Chromosome 6p22 in Bladder Cancer by Quantitative-Multiplex Polymerase Chain Reaction. American Journal Of Pathology. 164(1). 285–293. 45 indexed citations

15.

Squire, Jeremy A., Jianming Pei, Paula Marrano, et al.. (2003). High‐resolution mapping of amplifications and deletions in pediatric osteosarcoma by use of CGH analysis of cDNA microarrays. Genes Chromosomes and Cancer. 38(3). 215–225. 126 indexed citations

16.

Kolomietz, Elena, Paula Marrano, Karen Yee, et al.. (2003). Quantitative PCR identifies a minimal deleted region of 120 kb extending from the Philadelphia chromosome ABL translocation breakpoint in chronic myeloid leukemia with poor outcome. Leukemia. 17(7). 1313–1323. 27 indexed citations

17.

Zieleńska, Maria, Kwan Ng, Paula Marrano, et al.. (2001). Acquisition of secondary structural chromosomal changes in pediatric ewing sarcoma is a probable prognostic factor for tumor response and clinical outcome. Cancer. 91(11). 2156–2164. 46 indexed citations

18.

Zieleńska, Maria, Jane Bayani, Ajay Pandita, et al.. (2001). Comparative genomic hybridization analysis identifies gains of 1p35∼p36 and chromosome 19 in osteosarcoma. Cancer Genetics and Cytogenetics. 130(1). 14–21. 58 indexed citations

19.

Bayani, Jane, Maria Zieleńska, Paula Marrano, et al.. (2000). Molecular cytogenetic analysis of medulloblastomas and supratentorial primitive neuroectodermal tumors by using conventional banding, comparative genomic hybridization, and spectral karyotyping. Journal of neurosurgery. 93(3). 437–448. 108 indexed citations

20.

Thorner, Paul S., Reuben Baumal, V. E. Valli, et al.. (1989). Abnormalities in the NC1 domain of collagen type IV in GBM in canine hereditary nephritis. Kidney International. 35(3). 843–850. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact